Bio-Techne (TECH) EBITDA (2009 - 2026)

Bio-Techne's EBITDA history runs 18 years deep, the most recent figure standing at $75.5 million for Q1 2026.

• In Q1 2026, EBITDA rose 95.04% year-over-year to $75.5 million; the TTM figure through Mar 2026 stood at $153.8 million (down 10.58% YoY), while the FY2025 annual figure was $102.3 million, down 50.53% from the prior year.
• EBITDA for Q1 2026 stood at $75.5 million, up from $54.5 million in the prior quarter.
• The five-year high for EBITDA was $94.5 million in Q2 2023, with the low at -$23.9 million in Q2 2025.
• The 5-year median for EBITDA is $55.9 million (2023), against an average of $56.3 million.
• The sharpest annual moves came in 2025 and 2026: EBITDA slumped 152.07% in 2025, then jumped 95.04% in 2026.
• Bio-Techne's EBITDA stood at $67.9 million in 2022, then tumbled by 44.02% to $38.0 million in 2023, then climbed by 24.77% to $47.4 million in 2024, then gained by 14.85% to $54.5 million in 2025, then jumped by 38.62% to $75.5 million in 2026.
• Business Quant data shows TECH's EBITDA at $75.5 million in Q1 2026, $54.5 million in Q4 2025, and $47.7 million in Q3 2025.